HomeCompareSMIT vs PFE

SMIT vs PFE: Dividend Comparison 2026

SMIT yields 13333.33% · PFE yields 6.20%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SMIT wins by $944051876715324800.00M in total portfolio value
10 years
SMIT
SMIT
● Live price
13333.33%
Share price
$0.02
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$944051876715324800.00M
Annual income
$930,326,183,604,330,300,000,000.00
Full SMIT calculator →
PFE
Pfizer Inc.
● Live price
6.20%
Share price
$27.76
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$51.1K
Annual income
$27,210.54
Full PFE calculator →

Portfolio growth — SMIT vs PFE

📍 SMIT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSMITPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SMIT + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SMIT pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SMIT
Annual income on $10K today (after 15% tax)
$1,133,333.33/yr
After 10yr DRIP, annual income (after tax)
$790,777,256,063,680,700,000,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$526.66/yr
After 10yr DRIP, annual income (after tax)
$23,128.96/yr
At 15% tax rate, SMIT beats the other by $790,777,256,063,680,700,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SMIT + PFE for your $10,000?

SMIT: 50%PFE: 50%
100% PFE50/50100% SMIT
Portfolio after 10yr
$472025938357662400.00M
Annual income
$465,163,091,802,165,140,000,000.00/yr
Blended yield
98.55%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

SMIT
No analyst data
Altman Z
-1.0
Piotroski
2/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-0.9% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SMIT buys
0
PFE buys
0
No recent congressional trades found for SMIT or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSMITPFE
Forward yield13333.33%6.20%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$944051876715324800.00M$51.1K
Annual income after 10y$930,326,183,604,330,300,000,000.00$27,210.54
Total dividends collected$943142383073684224.00M$60.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SMIT vs PFE ($10,000, DRIP)

YearSMIT PortfolioSMIT Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$1,344,033$1,333,333.33$9,161$701.38+$1.33MSMIT
2$168,918,905$167,480,789.20$8,610$859.79+$168.91MSMIT
3$19,852,785,021$19,672,041,793.12$8,366$1,081.25+$19852.78MSMIT
4$2,182,013,981,744$2,160,771,501,770.83$8,483$1,405.66+$2182013.97MSMIT
5$224,287,824,199,531$221,953,069,239,064.90$9,084$1,907.24+$224287824.19MSMIT
6$21,561,870,489,323,890$21,321,882,517,430,390.00$10,418$2,732.78+$21561870489.31MSMIT
7$1,938,749,165,623,537,400$1,915,677,964,199,961,300.00$13,007$4,193.56+$1938749165623.52MSMIT
8$163,055,200,603,353,700,000$160,980,738,996,136,500,000.00$18,010$7,005.87+$163055200603353.69MSMIT
9$12,827,750,571,022,997,000,000$12,653,281,506,377,408,000,000.00$28,216$12,979.89+$12827750571022998.00MSMIT
10$944,051,876,715,324,800,000,000$930,326,183,604,330,300,000,000.00$51,081$27,210.54+$944051876715324800.00MSMIT

SMIT vs PFE: Complete Analysis 2026

SMITStock

Schmitt Industries, Inc., together with its subsidiaries, designs, manufactures, and sells test and measurement products worldwide. The company operates through two segments, Measurement and Ice Cream. The Measurement segment designs, manufactures, and sells laser and confocal chromatic white light sensors for distance measurement and dimensional sizing products under the Acuity brand name for various industrial applications, including manufacturing, lumber production, steel casting, glass and paper production, medical imaging, crane control and micron-level part, and surface inspection. It also offers AR550 high speed laser sensor for application in vibration measurements, scanning of roads, vehicle crash tests, and ballistic measurements; AS2100, an accurate distance sensor, used in metal production, transportation industry, process control, and fill level measurement applications; and satellite focused remote tank monitoring products under the Xact brand that measure the fill levels of tanks holding propane, diesel, and other tank-based liquids, as well as related monitoring services, including transmission of fill data from the tanks via satellite to a secure website for display. The Ice Cream segment manufactures, wholesales, and retails ice creams and ice cream cakes, as well as sells through its website; and serves ice cream at catering events and holds various community-building events comprising ice cream classes, and live comedy and music performances through Ample Hills Creamery brand. Schmitt Industries, Inc. was founded in 1984 and is headquartered in Portland, Oregon.

Full SMIT Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this SMIT vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SMIT vs SCHDSMIT vs JEPISMIT vs OSMIT vs KOSMIT vs MAINSMIT vs JNJSMIT vs MRKSMIT vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.